Johnson & Johnson’s mixed Q3 results and prognosis imply a neutral short-term outlook for the stock.While solid performance in Consumer and Pharma segments is encouraging, the company faces challenges in MD&D, including DePuy’s struggles and persistent macroeconomic pressures impacting procedure volumes. The rosy outlook for new pharmaceutical launches is positive but largely priced in.The recent dip in gross and operating margins is partially attributed to temporary factors, namely OTC remediation and Crucell integration costs, which should ease in 2012. The stock is likely to remain stable in the near term, pending any significant changes in the broader healthcare landscape. 
0